K-7174
Based on 15 publication(s) in Google Scholar
K-7174 is an orally active proteasome and GATA inhibitor. K-7174 is a cell adhesion inhibitor. K-7174 induces cell apoptosis. K-7174 shows antitumor activities, it can be used for the research of cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.43%
- CAS No.: 191089-59-5
- Formule: C33H48N2O6
- Masse moléculaire:568.74
-
Stockage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Ubiquitination Compound Library
HY-L050
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Anti-Blood Cancer Compound Library
HY-L079
-
Protease Inhibitor Library
HY-L147
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) K-7174
More- Adv Sci (Weinh). 2025 Apr;12(16):e2404311. [Abstract]
- J Clin Invest. 2024 Aug 15:e175023. [Abstract]
- Biomaterials. 2021 Aug:275:120967. [Abstract]
- Sci Adv. 2025 Apr 11;11(15):eadk6989. [Abstract]
- Cell Rep Med. 2022 Mar 15;3(3):100561. [Abstract]
- Adv Healthc Mater. 2024 Jul;13(18):e2304439. [Abstract]
- FASEB J. 2020 Mar;34(3):4462-4481. [Abstract]
- J Assist Reprod Genet. 2024 Oct;41(10):2759-2770. [Abstract]
- Brain Res. 2023 Feb 15:1801:148203. [Abstract]
- FEBS Open Bio. 2020 Sep;10(9):1880-1890. [Abstract]
- Growth Horm IGF Res. 2025 May 21:82:101659. [Abstract]
- Biochem Genet. 2024 Dec 16. [Abstract]
- Research Square Preprint. 2020 Dec.
- Seoul National University. 2020 May.
- bioRxiv. 2019 Sep.
Customer Validation & Images
-
IF
-
WB
Activité biologique
K-7174 (10 μM; 1 h) inhibits the adhesion by VCAM-1 and its ligand[1]. K-7174 (1-30 μM; 1 h) dose-dependently suppresses the VCAM-1 expression with an IC50 value of 14 μM[1]. K-7174 (1-30 μM; 1 h) dose-dependently suppresses the induction of VCAM-1 mRNA by TNFα with an IC50 value of 9 μM[1]. K-7174 (10-20 μM; 24 h) dose-dependently rescues Epo production by Hep3B cells[2]. K-7174 (2.5-30 μM; 24 h) inhibits the binding activity of GATA[2]. K-7174 (0-25 μM; 72 h) inhibits MM cells growth and induces cell apoptosis[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:KMS12-BM, U266, and RPMI8226 cell lines
-
Concentration:0-25 μM
-
Incubation Time:72 h
-
Result:Inhibited MM cells growth.
-
Cell Line:KMS12-BM, U266, and RPMI8226 cell lines
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Significantly increased apoptosis of MM cells with the increasing percentage of annexin-V-positive cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR mice with IL-β or TNF-α injection[2]
-
Dosage:30 mg/kg
-
Administration:Intraperitoneal injection; 30 mg/kg once daily for 9 days
-
Result:Increased erythropoietin (Epo) production, reticulocyte counts, and hemoglobin (Hb) concentrations
-
Animal Model:NOD/SCID mice with murine xenograft[3]
-
Dosage:75 mg/kg
-
Administration:Intraperitoneal injection; once daily for 14 days
-
Result:Significantly decreased tumor volume, but showed a significant body weight reduction after 10 days.
-
Animal Model:NOD/SCID mice with murine xenograft[3]
-
Dosage:50 mg/kg
-
Administration:Oral gavage; once daily for 14 days
-
Result:Showed an anti-myeloma activity. Proved oral administration is more effective than intraperitoneal injection.
Chemical Information
-
CAS No. 191089-59-5
-
Appearance Oil
-
Masse moléculaire 568.74
-
Formule C33H48N2O6
-
Color Colorless to light yellow
-
SMILES
COC1=C(OC)C(OC)=CC(/C=C/CCCN2CCN(CCC/C=C/C3=CC(OC)=C(OC)C(OC)=C3)CCC2)=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
2025 Apr;12(16):e2404311. PMID: 40040621 -
J Clin Invest
2024 Aug 15:e175023. PMID: 39146021 -
Biomaterials
2021 Aug:275:120967. PMID: 34153786 -
Sci Adv
Androgen receptor-regulated lncRNA PRCAT71 promotes AR signaling through the interaction with KHSRP in prostate cancer. [Abstract]2025 Apr 11;11(15):eadk6989. PMID: 40203114 -
Cell Rep Med
2022 Mar 15;3(3):100561. PMID: 35492874 -
Adv Healthc Mater
Unveiling the Impact of Hemodynamics on Endothelial Inflammation-Mediated Hepatocellular Carcinoma Metastasis Using a Biomimetic Vascular Flow Model. [Abstract]2024 Jul;13(18):e2304439. PMID: 38486060 -
FASEB J
Differentiation of c-Kit+ CD24+ natural killer cells into myeloid cells in a GATA-2-dependent manner. [Abstract]2020 Mar;34(3):4462-4481. PMID: 31989715 -
J Assist Reprod Genet
SIRT5 suppresses the trophoblast cell proliferation, invasion, and migration to promote preeclampsia via desuccinylating HOXB3. [Abstract]2024 Oct;41(10):2759-2770. PMID: 39145876 -
Brain Res
Small molecule compound K-7174 attenuates neuropsychiatric manifestations in lupus-prone mice. [Abstract]2023 Feb 15:1801:148203. PMID: 36521514
K-7174 purchased from MedChemExpress. Usage Cited in: Brain Res. 2023 Feb 15:1801:148203. [Abstract]
K-7174 (30 mg/kg; i.p.; 3 times a week for 6 weeks) improves lupus-like symptoms in MRL/lpr mice. The deposition of IgG and C3 in the kidneys of mice in the MRL/lpr group is significantly higher than that in the control group, but K-7174 can significantly inhibit this deposition.
K-7174 purchased from MedChemExpress. Usage Cited in: Brain Res. 2023 Feb 15:1801:148203. [Abstract]
K-7174 significantly increases the protein and gene levels of ZO1 and Occludin in NPSLE model mouse (MRL/lpr mice) brain.
-
FEBS Open Bio
Chemokine-like factor 1 (CKLF1) aggravates neointimal hyperplasia through activating the NF-κB /VCAM-1 pathway. [Abstract]2020 Sep;10(9):1880-1890. PMID: 32741140 -
Growth Horm IGF Res
2025 May 21:82:101659. PMID: 40413916 -
Biochem Genet
Let-7c-5p Targeting CHD7 Hinders Cervical Cancer Migration and Invasion by Regulating Cell Adhesion. [Abstract]2024 Dec 16. PMID: 39680330 -
-
-
Solvant et solubilité
DMSO : 100 mg/mL (175.83 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Umetani M, et al. A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA. Biochem Biophys Res Commun. 2000 Jun 7;272(2):370-4. [Content Brief]
[2]. Imagawa S, et al. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB J. 2003 Sep;17(12):1742-4. [Content Brief]
[3]. Kikuchi J, et al. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases. J Biol Chem. 2013 Aug 30;288(35):25593-602. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7583 mL | 8.7914 mL | 17.5827 mL | 43.9568 mL |
| 5 mM | 0.3517 mL | 1.7583 mL | 3.5165 mL | 8.7914 mL | |
| 10 mM | 0.1758 mL | 0.8791 mL | 1.7583 mL | 4.3957 mL | |
| 15 mM | 0.1172 mL | 0.5861 mL | 1.1722 mL | 2.9305 mL | |
| 20 mM | 0.0879 mL | 0.4396 mL | 0.8791 mL | 2.1978 mL | |
| 25 mM | 0.0703 mL | 0.3517 mL | 0.7033 mL | 1.7583 mL | |
| 30 mM | 0.0586 mL | 0.2930 mL | 0.5861 mL | 1.4652 mL | |
| 40 mM | 0.0440 mL | 0.2198 mL | 0.4396 mL | 1.0989 mL | |
| 50 mM | 0.0352 mL | 0.1758 mL | 0.3517 mL | 0.8791 mL | |
| 60 mM | 0.0293 mL | 0.1465 mL | 0.2930 mL | 0.7326 mL | |
| 80 mM | 0.0220 mL | 0.1099 mL | 0.2198 mL | 0.5495 mL | |
| 100 mM | 0.0176 mL | 0.0879 mL | 0.1758 mL | 0.4396 mL |
Powered by Bioz